1. Introduction {#sec1}
===============

Plasma is the fourth state of matter besides the solid, liquid, and gaseous states. It is an ionized gas consisting of ions, a broad spectrum of radicals, ultraviolet irradiation, electric fields, and ozone, which are responsible for its antimicrobial efficacy \[[@B1]\].

Atmospheric pressure plasma is also called nonthermal plasma, because it can achieve body temperature \[[@B2]\]. This allows medical application to humans by small plasma hand device on humans \[[@B3]\]. Plasma medicine is a new scientific field, and many research groups investigated various applications, for example, to the treatment of dental diseases like periodontitis \[[@B4]\], peri-implantitis \[[@B5]\], and caries and denture stomatitis \[[@B6]\] as well as dermatological diseases and chronic wounds \[[@B1], [@B7], [@B8]\]. Most applications were based on the antimicrobial effect of plasma to disinfect the skin, implants, and other medical devices. To date antiseptics have been commonly applied in these cases.

Plasma is especially interesting for fields with a dissatisfactory standard therapy or where an effective therapy does not exist, for example, peri-implantitis therapy in dentistry. The antimicrobial efficacy of plasma could be increased by raising the electrical input power \[[@B9], [@B10]\]. However, plasma should also be tissue tolerable and applicable to humans. As with any active substance the balance between efficacy and tolerability needs to be found.

To enhance plasma effects without an increased input power, we investigated possible synergistic effects between atmospheric pressure plasma and different antiseptics including chlorhexidine, octenidine, and polyhexanide as well as the chemicals sodium hypochlorite and hydrogen peroxide, often used in dental practice, and the chelating agent EDTA.

2. Material and Methods {#sec2}
=======================

We used three different dental biofilm models grown on titanium, the typical dental implant material. Titanium discs were machined and had a diameter of 5 mm and 1 mm thickness (Straumann, Basel, Switzerland).

2.1. Monospecies Biofilm *Streptococcus mutans* {#sec2.1}
-----------------------------------------------

*Streptococcus mutans* (*S. mutans* DSM 20523, German collection of microorganisms and tissue culture cells, Braunschweig, Germany), a strain often utilized for antimicrobial tests, was grown overnight at 37°C on Columbia sheep blood agar (BBL, BD, Heidelberg, Germany). One inoculation loop of this culture was resuspended into 30 mL Brain Heart Infusion (BHI) (BD, BBL, Heidelberg, Germany) complemented with 1% sucrose \[[@B11]\]. The sterile titanium discs were positioned in 96-well microtiter plates (Techno Plastic Products AG, Trasadingen, Switzerland), covered with 100 *μ*L *S. mutans* suspension, and incubated aerobically at 37°C. For *S. mutans*, we deliberately used no surface coating with salivary proteins, since this reduces the contact angle of titanium, and, consequently, adhesion of *S. mutans* would be reduced \[[@B12]\]. In preliminary tests we achieved the best biofilm forming results without a conditioning film. Every 24 h BHI was changed. After 72 h the medium was drawn off, the discs were washed with 0.9% NaCl solution and transferred into a new, sterile microtiter plate.

2.2. Multispecies Saliva Biofilm {#sec2.2}
--------------------------------

To simulate a perimucositis situation, we used a multispecies saliva biofilm. Unstimulated saliva was taken from healthy donors (*n* = 5, pooled saliva, mean age 29 ± 7 years, nonsmokers) as a source of oral microbiota. This was approved by the local ethics committee (BB 120/10). Saliva donors did not take any medication three months prior to the study and did not have active carious lesions or overt periodontal disease. In the saliva of three donors we found *Aggregatibacter actinomycetemcomitans* and *Porphyromonas gingivalis*, and *Fusobacterium nucleatum* in four donors and *Streptococcus sanguinis* in all five donors in a PCR analysis. These bacteria are typically associated with periodontitis, perimucositis, or peri-implantitis.

Sterile titanium discs were covered with 100 *μ*L saliva and incubated aerobically at 37°C. We deliberately used no previous surface coating with salivary proteins, because we inoculated full saliva containing all proteins. The further procedure was as described above.

2.3. Multispecies Subgingival Biofilm {#sec2.3}
-------------------------------------

To study possible synergistic effects in an anaerobic milieu, we used a multispecies subgingival biofilm. Subgingival plaque was obtained from five periodontal patients (pooled plaque, mean age 50 ± 10 years). It was removed with a dental curet and resuspended in Schädler broth with vitamin K1 (BD, BBL, Heidelberg, Germany). The plaque was incubated at 37°C overnight under anaerobic conditions using the Anaerocult A system (Merck, Darmstadt, Germany) to develop a biofilm. Before biofilm formation the sterile titanium discs were conditioned with DTT saliva. To this end, 10 mL saliva was collected from healthy donors, pooled, and treated with 5 mL 1 M DL-dithiothreitol solution (DTT, Sigma-Aldrich, Steinheim, Germany) and 5 mL distilled water. This DTT saliva mixture was then centrifuged (Mini Spin, Eppendorf, Hamburg Germany). Thereafter the supernatant was filtered through a 0.2 *μ*m pore filter (HVM Filtramed, Rotenburg an der Fulda, Germany) and frozen at −20°C until use. The titanium discs were covered with 500 *μ*L DTT saliva and incubated 2 h at 37°C. Afterwards the DTT saliva was carefully removed, and 1 mL plaque suspension was added and incubated anaerobically at 37°C.

2.4. Antiseptic and Chemical Pretreatment {#sec2.4}
-----------------------------------------

Titanium discs were pretreated with 0.1% chlorhexidine digluconate (CHX, aqueous solution, Fagron GmbH & Co. KG, Barsbüttel, Germany), 0.1% octenidine dihydrochloride (OCT, Schülke & Mayr GmbH, Norderstedt, Germany), 0.1% polihexanide (PHMB, B. Braun, Melsungen, Germany), 0.6% sodium hypochlorite (NaOCl, AppliChem GmbH, Darmstadt, Germany), 1.5% hydrogen peroxide (H~2~O~2~, AppliChem GmbH, Darmstadt, Germany), and 20% ethylenediaminetetraacetic acid (EDTA, AppliChem GmbH, Darmstadt, Germany). As negative control we used 0.9% NaCl solution, hereafter called "NaCl control."

Biofilm discs were covered with 100 *μ*L of the substances and incubated for 30 min. Within this incubation time, antiseptically pretreated biofilms were treated 1 min with plasma. Afterwards the antiseptic effect was halted by adding 1 mL inactivator. For inactivating PHMB effects we used 30 g/L Tween 80, 30 g/L saponin, 1.0 g/L histidin, and 1.0 g/L cystein. For CHX, OCT, and EDTA, the inactivator was Lipofundin MCT 20% (B. Braun, Melsungen, Germany). An inactivator consisting of 30 g/L Tween 80, 3 g/L lecithin, 1 g/L histidin and 5 g/L sodium thiosulfate was used to stop the effect of NaOCl and H~2~O~2~. All inactivators were proven by the quantitative suspension test according to DIN EN 1040 (German Institute for Standardisation).

2.5. Plasma Treatment {#sec2.5}
---------------------

To test the resistance of antiseptics against plasma treatment, we treated 5 mL of each antiseptic for 1 and 10 min with plasma. By spectral measurement (CHX: 231 nm, OCT: 213 nm, PHMB: 235 nm) we compared measurement results after plasma treatment with untreated antiseptics.

For plasma generation we used the atmospheric pressure plasma jet kINPen 09 (neoplas tools, Greifswald, Germany) \[[@B8]\]. Argon (Ar) gas flow was set to 5 slm (standard liters per minute). The flow rate was controlled by a flow controller (MKS Instruments, Munich, Germany). We had a constant pin-to-disc distance of 7 mm during the application. The kINPen was fixed in a computer driven 3 axes (*x*, *y*, *z*) motorized stage, under which a 96-well plate with the titanium discs was positioned. The plasma devices were consecutively driven from well to well, positioned centrally over the discs and remained in position for 1 min. To assess the effects of biofilm dehydration by gas flow, biofilms were treated with Ar gas without plasma generation. Additionally we investigated biofilms without gas or plasma treatment, hereafter called "control procedure."

After plasma treatment, titanium discs were placed into wells with 200 *μ*L 0.9% NaCl solution and the biofilm was removed by ultrasonic scaling. Serial dilutions of the resuspended biofilm solution were made by transferring 0.1 mL of the resultant suspension to 0.9 mL of fresh 0.9% NaCl solution. Afterwards an aliquot portion of 0.1 mL from each dilution was plated on Columbia sheep blood agar (BBL, BD, Heidelberg, Germany) and incubated aerobically at 37°C for 48 h for *S. mutans* and saliva. Resuspended plaque biofilms were plated on Schädler agar (BBL, BD, Heidelberg, Germany) and incubated anaerobically at 37°C for 48 h. The colonies were counted and expressed as colony forming units (CFU/mL).

2.6. Change in Treatment Order {#sec2.6}
------------------------------

In an additional experiment we changed the treatment order because we wanted to test the hypothesis that EDTA destroys the biofilm matrix to increase the plasma effect and that a higher antimicrobial effect after an increased radical induction of H~2~O~2~ by plasma treatment is observable. First saliva biofilms were treated with plasma, and then EDTA or H~2~O~2~ was added. After 30 min the antiseptic effect was halted by adding 1 mL inactivator as described above. Then, CFUs were determined.

2.7. Live-Dead Staining {#sec2.7}
-----------------------

Biofilms on discs were stained with fluorescein diacetate (FDA) and ethidium bromide (EB) to selectively stain living (green) and dead (red) bacteria \[[@B13]\]. Thereby 6 *μ*L of a FDA stock solution (5 mg/mL) and 3 *μ*L of an EB stock solution (1.25 mg/mL) were mixed in 1 mL 0.9% NaCl solution. The fluorescence was measured at excitation wavelengths of 485 nm and 530 nm and emission wavelengths of 530 nm and 630 nm on Berthold TriStar LB 941 (Berthold Technologies, Bad Wildbad, Germany). The division of the green fluorescent signal by the red fluorescent signal yielded the live-dead ratio. With the live-dead staining we tested the antimicrobial effect with all agents in both treatment orders on saliva biofilms. Additionally, samples were observed using a Zeiss CLSM510 Exciter confocal laser scanning microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany). Using Live-dead staining the antimicrobial effect was tested with all agents in both treatment orders on saliva biofilms.

2.8. Statistics {#sec2.8}
---------------

For all analyses, observed CFU values were transferred to their base 10 logarithm (referred to as log~10~CFU; for *S. mutans*: log⁡~10~(CFU + 1)). Continuous data are presented as mean ± standard deviation (SD).

The log⁡~10~-reduction factor (RF) for each treatment method was calculated \[[@B14]\].

To examine differences in log~10~CFU values between different procedures and admixture combinations, log~10~CFU values were compared for each agent versus the NaCl control within each procedure (within columns of [Table 1](#tab1){ref-type="table"}) and for each agent; differences between the NaCl control, Ar gas, and Ar plasma were pairwise evaluated (within rows of [Table 1](#tab1){ref-type="table"}) using two-sided Mann-Whitney *U* tests. To adjust for multiple testing within each step (comparisons within columns, resp., within rows), *P* values were corrected according to Bonferroni.

Differences in log~10~CFU values across different procedures (control procedure, Ar gas, and Ar plasma) and agents (NaCl control, CHX, OCT, PHMB, NaOCl, H~2~O~2~, and EDTA) were evaluated using linear regression analyses including the twofold interaction term of both factors (significant at *P* \< 0.10). Linear regression coefficients with their 95% confidence intervals (CI) were reported. *R* ^2^ quantifies the amount of variation explained by the model.

Differences of live-dead ratios across combinations of procedures and admixtures were evaluated using two-sided Mann-Whitney-*U*-tests. *P* values were corrected according to Bonferroni.

Statistical differences were considered significant at a level alpha of 5%. Statistical analyses were performed with STATA/SE 10.0 (Stata Corp LP, College Station, TX, USA) and R 2.13.0 (R Development Core Team, 2011).

3. Results {#sec3}
==========

The measured spectral data of the antiseptics before and after plasma treatment were identical (OCT: 0.5, CHX: 1, PHMB: 1.1), indicating that the agents were not modified by plasma.

3.1. Log~**10**~CFU Values after Administration of Agent Plus Plasma/Gas {#sec3.1}
------------------------------------------------------------------------

### 3.1.1. *S. mutans* Biofilm {#sec3.1.1}

The highest CFU reduction with no colonies being detected (values below detection limit) was achieved for six combinations ([Table 1](#tab1){ref-type="table"}): NaOCl with any procedure and H~2~O~2~ with any procedure.

Compared with the control procedure, all agents lead to significantly lower CFU values compared with the negative control (*P* \< 0.05). In combination with Ar gas, admixture of CHX (RF = 1.96), OCT (RF = 1.90), PHMB (RF = 3.39), NaOCl (RF = 6.91), and H~2~O~2~  (RF = 6.91) significantly reduced CFU values compared with NaCl controls. In combination with Ar plasma, admixture of PHMB (RF = 3.36), NaOCl (RF = 6.91), H~2~O~2~  (RF = 6.91), and EDTA (RF = 2.78) significantly reduced CFU values compared with NaCl controls.

Compared with the control procedure, only Ar plasma significantly reduced log~10~CFU values when combined with NaCl control, PHMB, or EDTA (*P* \< 0.05). For admixtures of CHX, OCT, NaOCl, and H~2~O~2~, log~10~CFU values did not differ significantly across procedures. For NaCl control and EDTA, log~10~CFU values were significantly reduced for Ar plasma compared with Ar gas (*P* \< 0.05).

To evaluate the impact of procedure and agents on *S. mutans* CFU values, linear regression models were evaluated ([Table 2](#tab2){ref-type="table"}). The model explained 98.4% of the variation in observed CFU values. Procedure, admixture, and the interaction of both were significantly related to log~10~(CFU/mL) values (*P* \< 0.001). Post hoc analysis confirmed that any combination with NaOCl or H~2~O~2~ was significantly the best performing combination among those tested (*P* \< 0.001) with a predicted reduction of 7.51 log~10~(CFU/mL) compared with NaCl control.

### 3.1.2. Saliva Biofilm {#sec3.1.2}

The highest reduction in log~10~CFU was found for the combination of Ar plasma with NaOCl (RF = 3.06, [Table 1](#tab1){ref-type="table"}). Compared with the control procedure, admixture of OCT, PHMB, NaOCl, H~2~O~2~, and EDTA led to significantly lower CFU values compared with the NaCl control (*P* \< 0.05). Combined with Ar gas, admixture of CHX, OCT, NaOCl, and H~2~O~2~ significantly reduced CFUs compared with NaCl control (*P* \< 0.05). The effect of Ar plasma on CFU reduction was significantly enhanced by OCT, NaOCl, and EDTA compared with the NaCl control.

Compared with the control procedure, application of Ar gas significantly reduced CFU values when CHX or OCT was applied previously (*P* \< 0.05). Compared with the control procedure, Ar plasma treatment significantly enhanced antimicrobial effects of NaCl control, CHX, OCT, PHMB, and EDTA (*P* \< 0.05). For NaCl control, OCT and EDTA, Ar plasma performed significantly better compared with Ar gas (*P* \< 0.05).

For the combination of plasma and agents, the simple additive effect on log~10~CFU reduction was partly exceeded. Compared with single reduction factors for plasma and CHX (RF = 1.48 and RF = 0.28, resp.), the combined RF was 1.70 ([Table 1](#tab1){ref-type="table"}).

Estimating the impact of procedure and agents on saliva log~10~CFU values more closely ([Table 2](#tab2){ref-type="table"}), linear regression models were performed, which explained 72.5% of the variation in observed CFU values. Procedure, admixture, and the interaction of both were significantly related to log~10~CFU values (*P* \< 0.001). Post hoc analyses revealed that the combination of Ar plasma with NaOCl was the best performing combination among those tested with a predicted reduction of 3.07 log~10~CFU compared with the total negative control (NaCl control with control procedure). It was significantly better compared with most combinations but similarly effective compared with Ar gas combined with NaOCl (*P* = 0.52), Ar plasma combined with OCT (*P* = 0.22), and Ar plasma combined with EDTA (*P* = 0.38).

### 3.1.3. Subgingival Biofilm {#sec3.1.3}

The highest log~10~CFU reduction was found for Ar plasma with H~2~O~2~ (4.41 ± 0.86, [Table 1](#tab1){ref-type="table"}). For the control procedure any admixture led to significantly reduced log~10~CFU values compared with NaCl control (*P* \< 0.05). With Ar gas, only the admixture of OCT was beneficial (log~10~CFU 4.68 ± 1.53). Regardless of the admixture, combinations with Ar plasma led to comparable reductions in log~10~CFU values.

Considering the effect of the three procedures within agents, both Ar gas and Ar plasma significantly reduced log~10~CFU values compared with the control procedure for NaCl control and H~2~O~2~. For PHMB, NaOCl, and EDTA, log~10~CFU values did not differ significantly across procedures. For NaCl control and H~2~O~2~, log~10~CFU values were significantly reduced for Ar plasma compared with Ar gas. The overall best log~10~CFU reduction was achieved when Ar plasma was combined with H~2~O~2~  (RF = 2.92).

To evaluate the impact of procedure and agents on plaque log~10~CFU values, linear regression models were evaluated ([Table 2](#tab2){ref-type="table"}). While 76.3% of the variation in observed log~10~CFU values were explained, procedure, admixture, and the interaction of both were significantly related to log~10~CFU values(*P* \< 0.001). Post hoc analyses revealed that the combination of Ar plasma with H~2~O~2~ was significantly the best performing combination among those tested (*P* \< 0.001) with the exception of Ar gas with OCT (*P* = 0.25). The combination of Ar plasma with H~2~O~2~ had a predicted reduction of 2.92 log~10~CFU compared with the total negative control (NaCl control with control procedure).

3.2. Log~**10**~CFU Values after Administration of Plasma Plus Agent {#sec3.2}
--------------------------------------------------------------------

To evaluate whether the reduction in CFU was related to the procedure or the admixture, the treatment order was changed; that is, plasma or gas was applied before the admixture of agents ([Table 3](#tab3){ref-type="table"}). The data were comparable with those of [Table 1](#tab1){ref-type="table"}. The extent of log~10~CFU reduction relative to the total negative control was comparable, irrespective of the treatment order. For example, the combination of EDTA plus Ar plasma achieved a log~10~CFU reduction of RF = 2.81, while the combination of both in reversed treatment order achieved a log~10~CFU reduction of RF = 2.66. For the combination of H~2~O~2~ with Ar plasma, respective log~10~CFU reductions were 2.41 and 2.58. Accordingly, we found an additive effect of the antimicrobial effects of plasma (RF~plasma~ = 1.35) and H~2~O~2~ (RF~H~2~O~2~~ = 1.00) when combined: RF~plasma+H~2~O~2~~ = 2.58 (\>1.35 + 1.00). The same figures applied to the combination of plasma (RF~plasma~ = 1.35) with EDTA (RF~EDTA~ = 1.25) and plasma + EDTA: RF~plasma+EDTA~ = 2.66(\~1.35 + 1.25).

3.3. Live-Dead Staining {#sec3.3}
-----------------------

To determine the antimicrobial effect of all combinations with both treatment orders, we stained the biofilms with EB and FDA ([Figure 1](#fig1){ref-type="fig"}). A reduction of the living microorganisms in % can be explained by a reduced FDA fluorescence or an increased EB fluorescence signal, resulting in a higher number of dead cells. The negative control achieved a mean value of 100%. For Ar plasma treated cells the value decreased to 45.3%. After EDTA treatment the mean living microorganisms of 56.4% were further reduced to 17.3% after additional plasma treatment. When EDTA treatment was applied after Ar plasma treatment, no additive effect was found (51%). Both values differed significantly between the two treatment orders (*P* \< 0.05).

Concerning antiseptics, additional Ar plasma treatment consistently decreased the mean ratio with only minimal differences between either treatment order (CHX: 24.4%, CHX + Ar plasma: 8.6%, and Ar plasma + CHX: 14.2%; OCT: 28.6%, OCT + Ar plasma: 3.4%; Ar plasma + OCT: 14.17; PHMB: 73%; PHMB + Ar plasma: 18.7%, Ar plasma + PHMB: 28.8%). Applying the antiseptic treatment before Ar plasma treatment led to slightly fewer living microorganisms compared with the other treatment order. This difference was significant (*P* \< 0.05) for OCT. For NaOCl, the lowest ratio was achieved when plasma treatment was applied prior to NaOCl treatment (17.4%; 21.9% when Ar plasma treatment was applied after NaOCl treatment). The highest reduction was achieved by H~2~O~2~ (5.4%). With prior (posterior) Ar plasma treatment the ratio was 1.6% (2.2%).

Using confocal laser scanning microscopy ([Figure 2](#fig2){ref-type="fig"}) the difference between the H~2~O~2~ treatments was more pronounced in the center of the disc, where no green fluorescence was visible. The micrographs for both treatment orders for the combination of EDTA and Ar plasma were comparable. Using the same microscopic settings the micrographs of Ar plasma and antiseptic after treated biofilms were comparable to those of EDTA and Ar plasma. Therefore the pictures have not been presented here.

4. Discussion {#sec4}
=============

In this study we found an additive antimicrobial effect between Ar plasma and agents irrespective of the treatment order regarding cultivation. Concerning Live-dead staining we found different antimicrobial effects dependent on treatment order.

Decontamination of dental implants is a promising application of plasma devices. To investigate synergistic effects between Ar plasma and agents, we used three different biofilm models.

In this study, sensitivity to treatments differed significantly between our biofilm models. Monospecies *S. mutans* biofilms were more susceptible to antimicrobial treatments than our multispecies biofilm models. *S. mutans* biofilm is no satisfactory model to test antibiofilm efficacy, because it cannot mimic oral conditions in an adequate way. Therefore we used biofilms cultured from *ex vivo* saliva and subgingival dental plaque to test Ar plasma in more realistic models. It was shown that Gram-negative as well as anaerobic bacteria are more sensitive to plasma than Gram positives or aerobic ones \[[@B15]\]. In multispecies saliva and subgingival biofilms we found both Gram-negative and -positive bacteria. We detected the highest CFU reduction by Ar plasma for the subgingival plaque biofilm. However, during biofilm processing we could not maintain the anaerobic atmosphere, which may have distorted the antimicrobial effect of the treatments.

Using only culture-based techniques to determine antimicrobial effects bears some disadvantages. Bacteria can exist in a viable but nonculturable state (VBNC) \[[@B16]\]. VBNC bacteria cannot be detected using culture-based techniques. Additionally, not all species in our multispecies biofilm grow on sheep blood agar. Therefore we used Live-dead staining with a microscopic and a spectroscopic analysis in saliva biofilms. This method showed more differences between treatment regimes.

In this study, we found additive effects between Ar plasma and agents. To understand the magnitude of these effects, we compared the CFU and live-dead ratio reduction of Ar plasma and the agents and the CFU and live-dead-ratio reduction of the combination of both.

Concerning culture-based technique, the antibiofilm effect of Ar plasma was significantly increased for *S. mutans* biofilms by adding EDTA. No colonies were detectable after NaOCl or H~2~O~2~ treatment. With anaerobic multispecies biofilms we found significant synergistic effects between H~2~O~2~ and Ar plasma, which was also the procedure with the highest log~10~CFU reduction of saliva biofilm. For aerobic multispecies saliva biofilms significant additive effects between Ar plasma and EDTA and OCT were found. Log~10~CFU reductions for combined treatments were always higher than single Ar plasma or single agent treatments.

Treatment order differed significantly between addition of EDTA and octenidine before or after plasma application (*P* \< 0.05) when we evaluated the results with Live-dead staining. When EDTA treatment was applied after Ar plasma treatment, no additive effect was found. Concerning antiseptics, additional Ar plasma treatment consistently decreased the mean ratio irrespective of the treatment order. For NaOCl, the lowest ratio was achieved when plasma treatment was applied prior to NaOCl treatment. The highest reduction was achieved by H~2~O~2~.

To our knowledge there are no studies that have investigated the combined effects of agents and plasma. To understand our observed results, we limit the discussion to studies that combined the agents with UV, ozone, and radicals. According to different mechanisms, agents used in this study can be classified into four groups: antiseptics (CHX, PHMB, and OCT), NaOCl, EDTA, and H~2~O~2~. With all agents, plasma interacts by the three main plasma constituents: UV radiation, ozone, and radicals. For each agent different mechanisms may be responsible for the increased effectivity of the combination of agent and plasma.

Firstly, no information has been published about interactions between radicals or radiation and antiseptics (CHX, PHMB, and OCT). After enquiry, the manufacturers confirmed UV stability of the products. Our spectral measurement of the antiseptics exposed before and after plasma treatment affirmed their information: antiseptics were not destroyed by the plasma treatment regime in our experiments. The antimicrobial efficacy of antiseptics was not decreased by additional plasma treatment as measured by CFU. For saliva biofilms the combination exceeded the pure plasma effect, which was corroborated by the live-dead staining experiment. Both treatment orders increased the antimicrobial effect, while prior plasma treatment tended to somewhat stronger antimicrobial effects. For OCT there was a significant difference between the two treatment orders: the biofilm could be destroyed by plasma so that the antiseptic could be more effective. Therefore, we might conclude that plasma does not destroy the antiseptics but rather has an additive effect in antiseptic treatment. For future medical therapies the combination of antiseptics and plasma treatment might be beneficial.

It was shown that the combination of UV and NaOCl increased the inactivation of some phages, but without any synergistic effects concerning *E.coli* and enterococci in waste water \[[@B17]\]. The synergistic effect between hypochlorite and radicals increases protein damage \[[@B18]\], which can be relevant for the increase in antimicrobial effects. Because of the high antimicrobial efficacy of NaOCl in single treatment, combinations with Ar plasma lead to comparable log~10~CFUs for saliva biofilm (*P* \> 0.05). Nevertheless, the combination with Ar plasma resulted in the highest CFU reduction factor, which was confirmed with Live-dead staining. The antimicrobial effect was not increased for NaOCl plus Ar plasma but for Ar plasma plus NaOCl. Regarding *S. mutans* biofilms and plaque our results are consistent.

Thirdly, the antibiofilm effect of EDTA is based on the dispersal of the biofilm structure \[[@B19]\]. Our working hypothesis was that after disruption of the biofilm matrix antimicrobial agents like plasma can kill the bacteria directly without being inhibited by the protective matrix. This explains why antibiotics can act more effectively with EDTA \[[@B20]\]. UV in combination with ozone or H~2~O~2~ is necessary for EDTA degradation, whereas pure ozone did not alter the action EDTA \[[@B21]\]. In plasma processes UV and ozone are developed. The resulting OH radicals degrade EDTA without creating toxic degradation products \[[@B22]\]. It is possible that EDTA was destroyed by plasma and the main effect of this combination is the dispersion of the biofilms by EDTA. EDTA showed per se an antimicrobial effect which could be increased using plasma. For *S. mutans* und saliva, Ar plasma plus EDTA was significantly more effective than Ar plasma or EDTA alone. According to our hypothesis, this synergistic effect is a consequence of the biofilm dispersion and the resulting better efficacy of plasma. To confirm this hypothesis, we changed the treatment order: first plasma, then EDTA. This order resulted in the same efficacy as that using CFU analysis. Using Live-dead staining we found only minimal differences between EDTA and plasma plus EDTA but a higher reduction of the live-dead ratio applying EDTA plus plasma (*P* \< 0.05). This confirmed our hypothesis in agreement with other research groups who have combined EDTA with antibiotics \[[@B20]\].

Fourthly, the synergistic UV-H~2~O~2~ effect is already known and is used to disinfect food packaging materials \[[@B23]\] and to clean waste water \[[@B24]\]. The mechanism is based on the photolysis of H~2~O~2~. The reaction is induced by the absorption of photons by hydrogen peroxide, which leads to the production of OH radicals \[[@B25]\]. According to our hypothesis the additionally formed radicals support antimicrobial effects of H~2~O~2~ and plasma. To test this hypothesis, we switched the treatment order of H~2~O~2~ and plasma too. We found the same synergistic reduction effect after switching the order using determination of CFU and Live-dead staining, whereas a prior H~2~O~2~ treatment tended to increase antimicrobial effects.

The antimicrobial effect of plasma may be attributed to a complex interaction of its components, for example, UV, radicals, ozone, and so forth. However, so far only single components such as UV have been combined with agents \[[@B18], [@B23], [@B26]\]. The current results deliver further information to understand antimicrobial effects of plasma in combination with agents as compared with effects of combinations between UV and agents because here a mixture of UV, radicals, and so forth was effective.

There are some studies which determined the cytotoxic potential of single treatments with plasma and agents \[[@B27]--[@B29]\]. The toxic potential of the combination of plasma and agents needs further clarification. More investigations are necessary to identify the underlying mechanisms.

We performed *in vitro* studies. However, *in vivo* studies are necessary to ensure that (i) antimicrobial effects are not restricted to *in vitro* settings and (ii) application of combined treatments with Ar plasma and agents in clinical settings is reasonable.

This is the first study evaluating the combined antimicrobial effect of plasma with different agents using three different biofilm models. The combination of plasma and agents increased the antimicrobial efficacy of all tested compounds. It supports the additional use of plasma treatment of dental implants in addition to the often used chemicals and antiseptic solutions. Thus, the combined treatment with plasma and agents seems very beneficial, since the efficacy will be increased, while no additional chemicals will be needed. Furthermore, our results indicate that even a reduction of commonly used agents could be possible when applied in combination with Ar plasma, which could reduce the costs for treatments as well as the possible risk for patients due to the antimicrobial agents.

This work was realized within the framework of the multidisciplinary research cooperation "Campus PlasmaMed", particularly within the project "PlasmaDent." The authors acknowledge that this work was supported by a grant funded by the German Ministry of Education and Research (BMBF, Grant no. 13N9779). All titanium discs were kindly provided by Straumann (Institut Straumann AG, Basel, Switzerland). The authors thank Claudia Lehnert for her excellent technical assistance, Rüdiger Titze for his skillful support in operating the plasma equipment, and Peter Meisel for critical reading of the paper.

![Green fluorescence (fluoresceindiacetate (FDA); alive): red fluorescence (ethidiumbromide (EB); damaged membrane dead) ratio of saliva biofilms after treatment with different procedures. Data are presented as mean ± SD (*n* = 8). \**P* \< 0.05 versus NaCl control (within equally colored columns); \*\**P* \< 0.05 versus Agent only for each agent separately; ^\#^ *P* \< 0.05 Plasma plus Agent versus Agent plus plasma for each agent separately. *P* values were retrieved from Mann-Whitney-*U* tests and were Bonferroni corrected.](ISRN.DENTISTRY2013-573262.001){#fig1}

![Fluorescence staining ofsaliva biofilms on titanium discs for different treatments: EDTA, EDTA plus Ar Plasma, Ar Plasma plus EDTA, H~2~O~2~, H~2~O~2~ plus Ar plasma and Ar plasma plus H~2~O~2~. The biofilms were stained with fluoresceindiacetate (FDA) and ethidiumbromide (EB) to selectively stain living (green) and dead (red) bacteria.](ISRN.DENTISTRY2013-573262.002){#fig2}

###### 

Logarithm of CFU/mL of *S. mutans*, saliva, and subgingival biofilms after treatment with different procedures (control compared with Ar gas or Ar plasma) and different agents (first agent then plasma).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agent          *S. mutans*         Saliva              Plaque                                                                                                                                  
  -------------- ------------------- ------------------- ------------------------- ------------------ ---------------------- ------------------------- ------------------ ---------------------- -----------------------
  NaCl control   6.91 ± 0.53  \      6.56 ± 0.70  \      4.80 ± 0.45^∗∗,\#^  \     7.39 ± 0.30  \     6.98 ± 0.56  \         5.91 ± 0.49^∗∗,\#^  \     7.33 ± 0.29  \     6.00 ± 0.49\*\*  \     5.17 ± 0.20^∗∗,\#^  \
                 N = 16              N = 8  \            *N* = 15  \               *N* = 32           *N* = 16  \            *N* = 38  \               *N* = 21           *N* = 14  \            *N* = 14  \
                                     RF = 0.35           RF = 2.11                                    RF = 0.41              RF = 1.48                                    RF = 1.33              RF = 2.16

                                                                                                                                                                                                 

  CHX            5.13 ± 0.15\*  \    4.95 ± 0.09\*  \    4.96 ± 0.14  \            7.11 ± 0.36  \     6.01 ± 0.70^∗,∗∗^  \   5.69 ± 0.65\*\*  \        6.59 ± 0.42\*  \   5.49 ± 0.12\*\*  \     5.34 ± 0.05\*\*  \
                 *N* = 8  \          *N* = 8  \          *N* = 8  \                *N* = 24  \        *N* = 16  \            *N* = 23  \               *N* = 7  \         *N* = 7  \             *N* = 7  \
                 RF = 1.78           RF = 1.96           RF = 1.95                 RF = 0.28          RF = 1.38              RF = 1.70                 RF = 0.74          RF = 1.84              RF = 1.99

                                                                                                                                                                                                 

  OCT            5.07 ± 0.16\*  \    5.01 ± 0.36\*  \    5.06 ± 0.12  \            6.60 ± 0.58\*  \   5.61 ± 0.57^∗,∗∗^  \   4.60 ± 0.64^∗,∗∗,\#^  \   5.80 ± 0.33\*  \   4.68 ± 1.53^∗,∗∗^  \   5.34 ± 0.05  \
                 *N* = 8  \          *N* = 8  \          *N* = 8  \                *N* = 22  \        *N* = 13  \            *N* = 30  \               *N* = 7  \         *N* = 7  \             *N* = 7  \
                 RF = 1.84           RF = 1.90           RF = 1.85                 RF = 0.79          RF = 1.78              RF = 2.79                 RF = 1.53          RF = 2.65              RF = 1.99

                                                                                                                                                                                                 

  PHMB           4.39 ± 0.22\*  \    3.52 ± 0.66\*  \    3.55 ± 0.24^∗,∗∗^  \      6.52 ± 0.54\*  \   6.26 ± 0.95  \         5.83 ± 0.48\*\*  \        6.37 ± 0.67\*  \   5.47 ± 0.26  \         5.26 ± 0.11  \
                 **N** = 7  \        *N* = 6  \          *N* = 7  \                *N* = 16  \        *N* = 8  \             *N* = 23  \               *N* = 7  \         *N* = 7  \             *N* = 7  \
                 RF = 2.52           RF = 3.39           RF = 3.36                 RF = 0.87          RF = 1.13              RF = 1.56                 RF = 0.96          RF = 1.86              RF = 2.07

                                                                                                                                                                                                 

  NaOCl          0 ± 0\*  \          0 ± 0\*  \          0 ± 0\*  \                5.00 ± 0.11\*  \   4.51 ± 0.60\*  \       4.33 ± 0.31\*  \          5.57 ± 0.06\*  \   5.59 ± 0.06  \         5.69 ± 0.03  \
                 **N** = 7  \        **N** = 7  \        **N** = 8  \              *N* = 6  \         *N* = 7  \             **N** = 8  \              *N* = 7  \         *N* = 7  \             *N* = 7  \
                 **RF** = **6.91**   **RF** = **6.91**   **RF** = **6.91**         RF = 2.39          RF = 2.88              **RF** = **3.06**         RF = 1.76          RF = 1.74              RF = 1.64

                                                                                                                                                                                                 

  H~2~O~2~       0 ± 0\*  \          0 ± 0\*  \          0 ± 0\*  \                5.90 ± 0.29\*  \   5.56 ± 0.54\*  \       4.98 ± 1.51  \            5.45 ± 0.06\*  \   5.49 ± 0.08  \         4.41 ± 0.86^\#^  \
                 **N** = 8  \        **N** = 7  \        **N** = 8  \              *N* = 8  \         *N* = 7  \             *N* = 8  \                *N* = 7  \         *N* = 7  \             **N** = 7  \
                 **RF** = **6.91**   **RF** = **6.91**   **RF** = **6.91**         RF = 1.49          RF = 1.83              RF = 2.41                 RF = 1.88          RF = 1.84              **RF** = **2.92**

                                                                                                                                                                                                 

  EDTA           5.79 ± 0.22\*  \    5.64 ± 0.32  \      4.13 ± 0.32^∗,∗∗,\#^  \   6.76 ± 0.11\*  \   6.67 ± 0.20  \         4.58 ± 0.62^∗,∗∗,\#^  \   5.60 ± 0.30\*  \   5.31 ± 0.10  \         5.25 ± 0.18  \
                 *N* = 9  \          *N* = 9  \          *N* = 7  \                *N* = 8  \         *N* = 8  \             *N* = 8  \                *N* = 7  \         *N* = 7  \             *N* = 7  \
                 RF = 1.12           RF = 1.27           RF = 2.78                 RF = 0.63          RF = 0.72              RF = 2.81                 RF = 1.73          RF = 2.02              RF = 2.08
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as mean lg (CFU/mL + 1) ± standard deviation. Ar: argon; CHX: 0.1% chlorhexidine; OCT: 0.1% octenidine; PHMB: 0.1% polyhexanide; NaOCl: 0.6% sodium hypochlorite; H~2~O~2~: 1.5% hydrogen peroxide; EDTA: 20% ethylenediaminetetraacetic acid.

Entries with the lowest CFUs/mL were boldface font.

\**P* \< 0.05 versus NaCl control (within columns); \*\**P* \< 0.05 versus control procedure (within rows); ^\#^ *P* \< 0.05 Ar plasma versus Ar gas (within rows), two-sided Mann-Whitney *U* tests, and reduction in respective CFUs/mL. *P* values were Bonferroni corrected.

###### 

Linear regression models evaluating effects of different agents and plasma procedures on lg (CFU/mL + 1) for *S. mutans*, saliva, and subgingival biofilms (first agent then plasma).

                                  *S. mutans* (*N* = 178, *R* ^2^ = 98.4%)   Saliva (*N* = 329, *R* ^2^ = 72.6%)   Subgingival (*N* = 175, *R* ^2^ = 76.3%)                                    
  ------------------------------- ------------------------------------------ ------------------------------------- ------------------------------------------ --------- ---------------------- ---------
  Agent (ref. NaCl control)                                                                                                                                                                     
   CHX                            −1.78 (−2.06; −1.50)                       \<0.001                               −0.29 (−0.59; 0.02)                        \<0.001   −0.74 (−1.12; −0.36)   \<0.001
   OCT                            −1.84 (−2.12; −1.56)                       \<0.001                               −0.79 (−1.10; −0.49)                       \<0.001   −1.54 (−1.91; −1.16)   \<0.001
   PHMB                           −2.51 (−2.81; −2.22)                       \<0.001                               −0.87 (−1.22; −0.53)                       \<0.001   −0.96 (−1.34; −0.58)   \<0.001
   NaOCl                          −6.91 (−7.20; −6.61)                       \<0.001                               −2.39 (−2.89; −1.90)                       \<0.001   −1.76 (−2.14; −1.38)   \<0.001
   H~2~O~2~                       −6.91 (−7.19; −6.63)                       \<0.001                               −1.50 (−1.94; −1.06)                       \<0.001   −1.89 (−2.27; −1.51)   \<0.001
   EDTA                           −1.11 (−1.38; −0.84)                       \<0.001                               −0.64 (−1.08; −0.19)                       0.005     −1.74 (−2.12; −1.36)   \<0.001
                                                                                                                                                                                               
  Procedure (ref. control)                                                                                                                                                                      
   Ar gas                         −0.35 (−0.63; −0.07)                       0.02                                  −0.42 (−0.76; −0.07)                       0.02      −1.34 (−1.64; −1.04)   \<0.001
   Ar plasma                      −2.10 (−2.34; −1.87)                       \<0.001                               −1.49 (−1.76; −1.22)                       \<0.001   −2.16 (−2.46; −1.86)   \<0.001
                                                                                                                                                                                               
  Interaction agent × procedure                                                                                                                                                                 
   CHX × Ar gas                   0.18 (−0.25; 0.60)                         0.42                                  −0.68 (−1.17; −0.19)                       0.008     0.24 (−0.31; 0.79)     0.40
   OCT × Ar gas                   0.29 (−0.14; 0.71)                         0.19                                  −0.58 (−1.10; −0.61)                       0.03      0.22 (−0.33; 0.78)     0.43
   PHMB × Ar gas                  −0.53 (−0.99; −0.07)                       0.02                                  0.15 (−0.44; 0.75)                         0.61      0.44 (−0.12; 0.99)     0.12
   NaOCl × Ar gas                 0.35 (−0.10; 0.79)                         0.12                                  −0.07 (−0.78; 0.64)                        0.84      1.35 (0.80; 1.91)      \<0.001
   H~2~O~2~ × Ar gas              0.35 (−0.09; 0.78)                         0.12                                  0.08 (−0.59; 0.75)                         0.81      1.38 (0.83; 1.94)      \<0.001
   EDTA × Ar gas                  0.19 (−0.22; 0.61)                         0.36                                  0.32 (−0.33; 0.98)                         0.33      1.05 (0.50; 1.61)      \<0.001
   CHX × Ar plasma                1.93 (1.53; 2.33)                          \<0.001                               0.08 (−0.34; 0.50)                         0.72      0.91 (0.35; 1.46)      0.001
   OCT × Ar plasma                2.09 (1.70; 2.49)                          \<0.001                               −0.51 (−0.92; −0.10)                       0.02      1.70 (1.15; 2.25)      \<0.001
   PHMB × Ar plasma               1.26 (0.85; 1.68)                          \<0.001                               0.80 (0.35; 1.25)                          0.001     1.04 (0.49; 1.60)      \<0.001
   NaOCl × Ar plasma              2.10 (1.70; 2.51)                          \<0.001                               0.81 (0.16; 1.47)                          0.02      2.27 (1.72; 2.82)      \<0.001
   H~2~O~2~ × Ar plasma           2.10 (1.70; 2.50)                          \<0.001                               0.57 (−0.05; 1.19)                         0.07      1.12 (0.57; 1.67)      \<0.001
   EDTA × Ar plasma               0.44 (0.04; 0.84)                          0.03                                  −0.69 (−1.31; −0.08)                       0.03      1.82 (1.26; 2.37)      \<0.001

Ar: argon; CHX: 0.1% chlorhexidine; OCT: 0.1% octenidine; PHMB: 0.1% polyhexanide; NaOCl: 0.6% sodium hypochlorite; H~2~O~2~: 1.5% hydrogen peroxide; EDTA: 20% ethylenediaminetetraacetic acid.

###### 

Logarithm of saliva biofilm CFU/mL after treatment with different procedures (control compared with Ar gas or Ar plasma) and different agents (NaCl, H~2~O~2~, and EDTA) in changed order (first plasma then agent treatment).

  --------------------------------------------------------------------------------
  Agent          Procedure                               
  -------------- ------------------ -------------------- -------------------------
  NaCl control   7.17 ± 0.48  \     6.59 ± 0.48\*\*  \   5.82 ± 0.52^∗∗,\#^  \
                 *N* = 21           *N* = 15             *N* = 8

  H~2~O~2~       6.17 ± 0.80\*  \   5.62 ± 0.86\*  \     4.59 ± 0.77^∗,∗∗,\#^  \
                 *N* = 14           *N* = 15             *N* = 11

  EDTA           5.92 ± 0.37\*  \   6.25 ± 0.43\*\*  \   4.51 ± 0.82^∗,∗∗,\#^  \
                 *N* = 8            *N* = 14             *N* = 16
  --------------------------------------------------------------------------------

Data are presented as mean lg (CFU/mL + 1) ± SD.

Ar: argon; CHX: 0.1% chlorhexidine; OCT: 0.1% octenidine; PHMB: 0.1% polyhexanide; NaOCl: 0.6% sodium hypochlorite; H~2~O~2~: 1.5% hydrogen peroxide; EDTA: 20% ethylenediaminetetraacetic acid.

\**P* \< 0.05 versus NaCl control (within columns); \*\**P* \< 0.05 versus control procedure (within rows); ^\#^ *P* \< 0.05 comparing Ar plasma versus Ar gas (within rows), two-sided Mann-Whitney *U* test, and reduction in saliva CFU/mL. *P* values were Bonferroni corrected.
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